Curcumin (the active compound in turmeric) shows up constantly in brain-health and anti-inflammatory marketing, almost always paired with piperine (black pepper extract) and a claim that piperine boosts absorption by up to 2000%. That number gets repeated on label after label as if it settles the question. It doesn't — it traces back to a single 1998 study measuring something narrower than "your body absorbs 20x more curcumin," and the research since then has not been kind to it. We went back to the original data and the replication attempts to see what actually holds up, because a bioavailability claim that big is exactly the kind of thing worth checking before it decides which supplement someone buys.
The bioavailability problem is real
Curcumin genuinely is poorly absorbed when taken orally: it's metabolized and eliminated rapidly, and very little reaches the bloodstream as active, unconjugated compound. It dissolves poorly in water, degrades quickly at normal gut pH, and gets tagged for elimination by liver and intestinal enzymes (glucuronidation and sulfation) almost as fast as it's absorbed. Studies that have looked for plain curcumin in human blood after a normal dose often can't find any measurable amount at all. This part isn't in dispute — it's why so much formulation effort has gone into fixing it, and why an ingredient that plausibly solved it would be worth taking seriously. Curcumin's whole pitch usually rests on inflammation, and the gap between the real mechanism there and the marketing built on top of it is its own subject, covered in inflammation and the brain.
Where the 2000% number actually comes from
The claim traces to Shoba et al., published in Planta Medica in 1998. Here is the detail that almost never travels with the number: the human arm of that study had eight participants, given a single 2g dose of curcumin.3 Curcumin alone produced serum levels the researchers described as "either undetectable or very low." That's the baseline the famous number is measured against. When 20mg of piperine was added, serum curcumin rose sharply — but only in a narrow window, roughly 15 to 60 minutes after dosing, before falling back down.2 The same study's rat arm, incidentally, found an increase of up to 154% — not 2000%. The headline figure is the human number, from eight people, on one occasion.
The UK's Committee on Toxicity has gone through this study and set out the problems plainly: the human arm had only eight participants, it measured curcumin itself rather than its metabolites and related compounds, and the control group's readings were below the limit of detection — which makes the assumptions behind the area-under-the-curve calculation, and therefore the percentage itself, unclear.3 A large percentage increase measured off a baseline the assay could not actually read, in a 45-minute spike, in eight people, is a different claim than "piperine makes curcumin supplements work better." It is the one that ended up on packaging.
There's also a measurement problem underneath the headline number, and it is worth stating precisely rather than loosely. The 1998 study measured curcumin itself, not the metabolites and related compounds the body produces from it.3 Several of the later studies did the harder thing and measured free, unconjugated curcumin separately — the fraction that is actually biologically available — and that is where piperine's apparent advantage disappears. That distinction matters more than it sounds: a molecule the liver has already glucuronidated for excretion doesn't behave like free curcumin once it's in circulation, so a serum reading that lumps both together can report a large number without telling you how much of it is actually usable. More curcumin showing up in a blood draw is not automatically the same claim as more curcumin reaching the tissues where its proposed effects would need to happen — and the original study's method simply wasn't built to separate those two things.
The famous fix doesn't replicate
Since 1998, at least four independent research groups have tested piperine directly and failed to replicate a meaningful benefit. Volak and colleagues at Tufts University in the United States (2013) found no meaningful change in curcumin pharmacokinetics from co-administered piperine. Flory and colleagues at Hohenheim University in Germany (2021) found piperine did not increase free curcumin levels, and that solubility-based formulations clearly outperformed it. Fança-Berthon and colleagues (2021), in 30 subjects, found piperine did not significantly increase curcumin blood levels. Kroon and colleagues at Amsterdam University Medical Center in the Netherlands (2025) found piperine raised neither unconjugated nor even total plasma curcumin.1 These weren't attempts to nitpick the original result over minor details — they used modern analytical methods capable of separating free curcumin from its metabolites, larger and more varied groups of participants, and, in several cases, followed blood levels over a longer window than the original study's single afternoon. None of them found the kind of dramatic, clinically meaningful shift the "2000%" figure implies. Being straight about the shape of this evidence: these are four studies that failed to find an effect, not one large definitive trial that ruled one out. Four independent failures to replicate is strong grounds for disbelieving the original claim. It is not the same as proof that piperine does nothing, and we won't overstate it in the other direction either.
The more clinically relevant trials are arguably the ones that measured outcomes people actually care about, not just blood levels — and they need reporting carefully, in two parts, because the two trials say different things.
On liver enzymes, a 2025 meta-analysis in non-alcoholic fatty liver disease found curcumin alone significantly reduced ALT and AST, while curcumin plus piperine showed no significant effect.1 That is a genuine point against the combination. On inflammatory bowel disease, a randomized trial in 51 patients found something less flattering to either version: neither arm showed significant improvement. Curcumin alone did not beat the combination there — both failed. What the combination group did produce was roughly four times more heartburn than the other groups.1 Read together: when researchers looked at what piperine does for people taking curcumin rather than what it briefly does to a blood sample, it added side effects without adding benefit — and in one of those two settings, curcumin on its own didn't work either.
A 2000% spike measured against an almost-undetectable baseline, in a 45-minute window that four later trials couldn't reproduce, is not evidence of a supplement that works better.
Why we haven't added it
Two honest formulations of curcumin actually do show substantially better absorption in trials — lipid-based micelle formulations at roughly 57x, and cyclodextrin complexes at roughly 30x, higher measured absorption than plain curcumin.1 Those are pharmacokinetic figures, and it is worth saying what they are not: better absorption is a necessary step toward a clinical effect, not evidence of one. A formulation that gets more curcumin into the blood still has to show it changes an outcome that matters, and that is a separate body of work. Those trials measure sustained blood levels over hours, not a brief spike off a near-zero starting point, which is a meaningfully different — and more convincing — kind of evidence. The mechanism is different, too: instead of trying to slow down the enzymes that clear curcumin from the body (which is what piperine attempts, with side effects attached), these approaches change the physical form of curcumin itself — encasing it in a lipid shell or a ring-shaped sugar molecule — so more of it survives digestion intact in the first place.
| Approach | What the evidence shows | Our read |
|---|---|---|
| Piperine co-administration | 2000% figure from a near-zero baseline in one 1998 trial; not replicated in 4 independent studies since; more heartburn reported | Not going in the range |
| Lipid-based micelle formulation | ~57x higher measured absorption vs. plain curcumin, sustained over hours (pharmacokinetics, not outcomes) | Promising; sourcing a clean version |
| Cyclodextrin complex | ~30x higher measured absorption vs. plain curcumin, sustained over hours (pharmacokinetics, not outcomes) | Promising; sourcing a clean version |
Those aren't what's on most shelves, though — most curcumin products still lead with the piperine claim the evidence doesn't support, and piperine itself carries a real interaction risk through inhibiting a liver enzyme (CYP3A4) involved in metabolizing many common medications, including some blood thinners, blood pressure drugs, and antidepressants — the same class of question we work through for our own range in Proco products and mental health medications. That's not a reason to panic about a pinch of black pepper on food — it's a reason to be more careful, not less, about a concentrated 20mg extract sold specifically to alter how your body processes another compound. Higher blood concentration also isn't automatically the same thing as more active compound reaching the tissues where curcumin's proposed benefits would need to happen — a distinction the original piperine study's measurement limitations make it impossible to speak to either way.
We'd rather wait for a clean, properly-formulated (micelle or cyclodextrin) single-ingredient option than sell the piperine version everyone else does. We don't currently sell curcumin in any form. This is the same call we made on magnesium L-threonate, for the same reason — an appealing mechanism and a thinner evidence base than the marketing implies, so we stayed with the form that had the data (why we use glycinate instead, for now). And it is why we won't claim an absorption edge for our own magnesium that no head-to-head trial has actually shown: the absorption evidence for glycinate is more limited than the category's marketing suggests, and we say so on the product page.
If you want the general skill rather than this one case: how to read a supplement label covers spotting this kind of claim, what a certificate of analysis actually tells you covers verifying what's in the bottle, and capsules versus gummies covers the other absorption question the category likes to make more of than the data supports.
Bottom line
Curcumin's underlying health evidence has real promise, but the absorption story attached to most products on the market — piperine as the fix — doesn't hold up under closer, more recent scrutiny. The original number came from a narrow spike over an almost-zero baseline, and four later trials couldn't reproduce a meaningful benefit from it. Until we can source a version using an enhancement method that's actually been shown to work, it's not going in the range.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability, incorporating the Shoba et al. (1998) piperine study and subsequent replication attempts (Volak 2013, Flory 2021, Fança-Berthon 2021, Kroon 2025). iScience. sciencedirect.com
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4):353–356, 1998. pubmed.ncbi.nlm.nih.gov
- "Statement on the potential risk to human health of turmeric and curcumin supplements — toxicokinetics." UK Committee on Toxicity (COT). cot.food.gov.uk
The standard this article is applying — and how often a well-marketed ingredient fails it — is set out in why we don't sell "brain blends".
Want to know the moment this changes? Join the list — no spam, just the range and the evidence behind it.